Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IoM seeks to augment Enzi/Kennedy bill

Executive Summary

The Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System seeks to work with Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.) on their "Enhancing Drug Safety & Innovation Act." "We certainly hope that when they start negotiations over that bill that the chair of our committee can go and testify in Congress and the bill can incorporate more of what is in the committee report," IoM Committee Study Director Kathleen Stratton said at the Academy of Managed Care Pharmacy Educational Conference Oct. 6. The committee's report, released in September, calls for sweeping changes at FDA (1The Pink Sheet" Oct. 2, 2006, p. 5)...

You may also be interested in...

FDA Drug Safety Reforms Not Enough To Fix Problems, IoM Committee Says

A separate postmarketing safety center may become necessary if the recommendations made by the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System do not result in sufficient reforms of FDA's safety oversight, the committee says

Kabi: US Pegfilgrastim Crowd Is An Opportunity For Us, Not A Deterrent

In the second part of Generics Bulletin’s exclusive interview with Fresenius Kabi’s senior vice president for biosimilars in the US, Ali Ahmed, he explains why Kabi is relishing the prospect of competing in pegfilgrastim and what the acquisition of mAbxience means for the company’s prospects and vision.

Next UK Drug Pricing Scheme Needs ‘Single-Digit Fixed Rebates’

The pharmaceutical industry and the UK government are beginning a series of round table discussions on the shape of the future voluntary drug pricing and access scheme (VPAS), ahead of the formal negotiations that are scheduled to start in April.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts